Support Centre
24 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

New application
Updating record

governing board
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
UKCCCR trial to study the effect on breast cancer mortality of annual mammographic screening starting at age 40
DOI 10.1186/ISRCTN24647151
ClinicalTrials.gov identifier
EudraCT number
Public title UKCCCR trial to study the effect on breast cancer mortality of annual mammographic screening starting at age 40
Scientific title
Acronym The 'Age' trial
Serial number at source G9000793
Study hypothesis To determine the effectiveness of mammographic screening starting at age 40, compared with starting at age 50, in reducing mortality from breast cancer.
Lay summary Not provided at time of registration
Ethics approval Ethics approval from Central London REC 98/2/40.
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Breast cancer
Participants - inclusion criteria Women aged 40-41 identified from Health Authorities registers
Participants - exclusion criteria Women under care for breast cancer may be removed from the prior notification list by the GPs prior to randomisation
Anticipated start date 30/07/1990
Anticipated end date 31/12/2010
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 195,000. Recruitment ceased at 160,000. Closed to recruitment - in follow-up.
Interventions Women in the intervention group are offered annual screening by mammography until the year of their 48th birthday. Screening is by 2-view mammography at 1st screen and single view subsequently. All women in both intervention and control groups will be invited for screening in the NHSBSP between the age of 50-52.
Primary outcome measure(s) Deaths from breast cancer in women free of the disease at trial entry in the two groups. Information on prognostic factors of all breast cancers is also collected.
Secondary outcome measure(s) Not provided at time of registration
Sources of funding 1. Medical Research Council (MRC) (UK)
2. Long -term follow up funded by National Institute for Health Research (NIHR) / Health Technology Assessment (HTA)
Trial website
Publications 1. 1999 protocol in http://www.ncbi.nlm.nih.gov/pubmed/10572845
2. 2002 Implications of pathologist concordance in http://www.ncbi.nlm.nih.gov/pubmed/11979379
3. 2006 results in http://www.ncbi.nlm.nih.gov/pubmed/17161727
4. 2010 assessment of contamination in the control group http://www.ncbi.nlm.nih.gov/pubmed/20233850
Contact name Dr  Sue  Moss
  Address Professor of Cancer Epidemiology
Centre for Cancer Prevention
Queen Mary University of London
Wolfson Institute of Preventive Medicine Charterhouse Square London
  City/town London
  Zip/Postcode EC1M 6BQ
  Country United Kingdom
  Tel +44 (0) 207 882 5841
  Email s.moss@qmul.ac.uk
Sponsor Medical Research Council (MRC) (UK)
  Address 20 Park Crescent
  City/town London
  Zip/Postcode W1B 1AL
  Country United Kingdom
  Tel +44 (0)20 7636 5422
  Fax +44 (0)20 7436 6179
  Email clinical.trial@headoffice.mrc.ac.uk
  Sponsor website: http://www.mrc.ac.uk
Date applied 06/04/2000
Last edited 12/06/2012
Date ISRCTN assigned 06/04/2000
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.